Table 1.

Comparison of Cell Types.

Cell Type Preclinical Animal Studies (n) Completed Clinical Studies at ClinicalTrials.gov (n) Change in Clinical Data
LVEF (%) EDV (mL) Change in Scar Size (%)
AMI ICM AMI ICM NIDCM AMI ICM NIDCM AMI ICM NIDCM AMI ICM
MSCs 335 133 4* 6 2 6.0 5.7 8.0 N/A −9.3 N/A −6.2 −25.9
CPCs 182 87 0 1§ 0 N/A 5.4 N/A N/A −12 N/A N/A −12
ESCs 3 0 0 1** 0 N/A 12.5 N/A N/A −14.5 N/A N/A N/A
iPSCs 3 0 0 0 0 N/A N/A N/A N/A N/A N/A N/A N/A
*References 65, 66, 112, and 113.
References 7174, 75, 114, and 115.
References 25 and 98
§Reference 116.
**Reference 41. Cells delivered via patch not intramyocardial.

Initial search criteria: Heart or cardiac, cells, completed studies, with results (=148 results on clinicaltrials.gov). An advanced search of these results was performed for “acute myocardial infarction,” “ischemic cardiomyopathy,” or “non-ischemic dilated cardiomyopathy,” each with the intervention of: “mesenchymal stem cells” for MSCs; “cardiosphere-derived stem cells” and “cardiopoietic stem cells” for CPCs; “embryonic stem cells” for ESCs; or “induced pluripotent stem cells” for iPSCs.

N/A, data not available.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2020 April; 11(2): e0015. ISSN: 2076-9172
Published online 2020 April 29. doi: 10.5041/RMMJ.10401